HER2-low heterogeneity and its impact on benefit from trastuzumab deruxtecan in metastatic breast cancer

被引：0
|
作者：
Zou, Y. [1 ]
Deng, X. [1 ]
Xie, J. [1 ]
Zeng, Y. [2 ]
Jing, B. [1 ]
Fu, J. [1 ]
Jiang, Y. [1 ]
Tang, H. [1 ]
Liu, P. [1 ]
Xie, X. [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, Dept Breast Oncol, Guangzhou, Peoples R China
[2] Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.10.059
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
37MO
引用
收藏
页码：S1418 / S1418
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness of Trastuzumab Deruxtecan for HER2-low Advanced Breast Cancer in the United States
    Bs, Ye Peng
    Wang, Liting
    Peng, Liubao
    Liu, Qiao
    Yi, Lidan
    Luo, Xia
    Li, Sini
    Qin, Shuxia
    Wan, Xiaomin
    Tan, Chongqing
    Chen, Guochun
    CLINICAL THERAPEUTICS, 2023, 45 (10) : 965 - 972
  • [22] Cost-effectiveness of trastuzumab deruxtecan for previously treated HER2-low advanced breast cancer
    Shi, Demin
    Liang, Xueyan
    Li, Yan
    Chen, Lingyuan
    PLOS ONE, 2023, 18 (08):
  • [23] Efficacy of trastuzumab deruxtecan in treating HER2-low breast cancer leptomeningeal metastasis: a case report
    Kharel, Zeni
    Stanford, Sarah
    Hemminger, Lauryn E.
    Schmidt, Tyler
    Hardy, Sara J.
    Zittel, Jason
    Mohile, Nimish A.
    Dhakal, Ajay
    PERSONALIZED MEDICINE, 2024, 21 (06) : 335 - 339
  • [24] Activity and tolerability of combination of trastuzumab deruxtecan with olaparib in preclinical HER2+and HER2-low breast cancer models
    Proia, Theresa
    Wallez, Yann
    Bashi, Azadeh Cheraghchi
    Wilson, Zena
    Randle, Suzanne
    Anderton, Mark
    Carroll, Danielle
    Rasheed, Zeshaan
    Pease, J. Elizabeth
    Leo, Elisabetta
    Mettetal, Jerome
    CANCER RESEARCH, 2022, 82 (04)
  • [25] Inter-Metastasis Heterogeneity of HER2-Low in Metastatic Breast Cancer
    Jaffer, Shabnam
    Bhardwaj, Swati
    LABORATORY INVESTIGATION, 2024, 104 (03) : S179 - S180
  • [26] Comparative survival analysis of patients with HER2-low and HER2-positive metastatic breast cancer with or without brain metastases treated with trastuzumab deruxtecan
    Podder, Vivek
    Ranjan, Tulika
    Bardhan, Mainak
    McCracken, Andrea
    Hurmiz, Charlie
    Ganiyani, Mohammad Arfat
    Ahmad, Shahzaib
    Mahtani, Reshma L.
    Ahluwalia, Manmeet Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [27] Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer
    Dickerson, James
    Moen, Marcus
    Nielsen, Perry
    Tran, Edward
    Suen, Wesley
    Goldhaber-Fiebert, Jeremy D.
    Alarid-Escudero, Fernando
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Economic Evaluation of Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer in the United States
    Lang, Yitian
    Wu, Bin
    Liu, Xiaoyan
    BREAST CANCER-TARGETS AND THERAPY, 2022, 14 : 453 - 463
  • [29] Enhertu (Fam-trastuzumab-deruxtecan-nxki) - Revolutionizing treatment paradigm for HER2-Low breast cancer
    Siddiqui, Tasmiyah
    Rani, Payal
    Ashraf, Tayyaba
    Ellahi, Aayat
    ANNALS OF MEDICINE AND SURGERY, 2022, 82
  • [30] Trastuzumab Deruxtecan in cerebral metastatic HER2-positive Breast Cancer
    Lorenz, Judith
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (04) : 354 - 354
12345